
Amylyx Pharmaceuticals, Inc.: shareholders and insiders
Price
$27.52
November 17, 2026Market cap $3.5B
What Ploutos Investor adds for Amylyx Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
$152.2K
1 person
Sold on the market
$17M
6 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan49%
- The rest51%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $51.3K by 1 person·sold $17M by 6 people
- 2025: bought $100.8K by 1 person, sold $94.4K by 1 person
- 2026: bought $51.3K by 1 person, sold $17M by 6 people
- Nov 10, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 10, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 10, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 9, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 9, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 9, 2026James M FratesChief Financial OfficerKind10b5-1
- Nov 9, 2026Justin B. KleeCo-Chief Executive OfficerKind10b5-1
- Nov 9, 2026Justin B. KleeCo-Chief Executive OfficerKind10b5-1
- Nov 9, 2026Joshua B CohenCo-Chief Executive OfficerKind10b5-1
- Nov 9, 2026Joshua B CohenCo-Chief Executive OfficerKind10b5-1
- Oct 5, 2026George M Milne JrDirectorKind10b5-1
- Sep 10, 2026Camille L BedrosianChief Medical OfficerKind
- Sep 10, 2026Camille L BedrosianChief Medical OfficerKind
- Sep 10, 2026James M FratesChief Financial OfficerKind
- Sep 10, 2026James M FratesChief Financial OfficerKind
- Sep 10, 2026Gina MazzarielloChief Legal OfficerKind
- Sep 10, 2026Gina MazzarielloChief Legal OfficerKind
- Sep 10, 2026Justin B. KleeCo-Chief Executive OfficerKind
- Sep 10, 2026Justin B. KleeCo-Chief Executive OfficerKind
- Sep 10, 2026Joshua B CohenCo-Chief Executive OfficerKind
- Sep 10, 2026Joshua B CohenCo-Chief Executive OfficerKind
- Aug 31, 2026Karen FirestoneDirectorKind
- Aug 31, 2026Karen FirestoneDirectorKind
- Aug 18, 2026James M FratesChief Financial OfficerKind
- Aug 18, 2026Justin B. KleeCo-Chief Executive OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | James M FratesChief Financial Officer | 10b5-1 | 20.0K | $6.88 | $137.6K | Form 4 |
| Nov 10, 2026 | James M FratesChief Financial Officer | 10b5-1 | 12.8K | $30.32 | $388.1K | Form 4 |
| Nov 10, 2026 | James M FratesChief Financial Officer | 10b5-1 | 7,200 | $30.97 | $223.0K | Form 4 |
| Nov 9, 2026 | James M FratesChief Financial Officer | 10b5-1 | 20.0K | $6.88 | $137.6K | Form 4 |
| Nov 9, 2026 | James M FratesChief Financial Officer | 10b5-1 | 7,700 | $29.39 | $226.3K | Form 4 |
| Nov 9, 2026 | James M FratesChief Financial Officer | 10b5-1 | 12.3K | $30.11 | $370.4K | Form 4 |
| Nov 9, 2026 | Justin B. KleeCo-Chief Executive Officer | 10b5-1 | 37.5K | $29.39 | $1.1M | Form 4 |
| Nov 9, 2026 | Justin B. KleeCo-Chief Executive Officer | 10b5-1 | 62.5K | $30.11 | $1.9M | Form 4 |
| Nov 9, 2026 | Joshua B CohenCo-Chief Executive Officer | 10b5-1 | 38.1K | $29.39 | $1.1M | Form 4 |
| Nov 9, 2026 | Joshua B CohenCo-Chief Executive Officer | 10b5-1 | 61.9K | $30.11 | $1.9M | Form 4 |
| Oct 5, 2026 | George M Milne JrDirector | 10b5-1 | 30.0K | $27.70 | $830.9K | Form 4 |
| Sep 10, 2026 | Camille L BedrosianChief Medical Officer | 7,947 | $32.21 | $256.0K | Form 4 | |
| Sep 10, 2026 | Camille L BedrosianChief Medical Officer | 2,081 | $33.09 | $68.9K | Form 4 | |
| Sep 10, 2026 | James M FratesChief Financial Officer | 9,768 | $32.27 | $315.2K | Form 4 | |
| Sep 10, 2026 | James M FratesChief Financial Officer | 1,042 | $33.23 | $34.6K | Form 4 | |
| Sep 10, 2026 | Gina MazzarielloChief Legal Officer | 9,525 | $32.46 | $309.1K | Form 4 | |
| Sep 10, 2026 | Gina MazzarielloChief Legal Officer | 11 | $33.34 | $367 | Form 4 | |
| Sep 10, 2026 | Justin B. KleeCo-Chief Executive Officer | 29.0K | $32.13 | $932.6K | Form 4 | |
| Sep 10, 2026 | Justin B. KleeCo-Chief Executive Officer | 1,439 | $33.16 | $47.7K | Form 4 | |
| Sep 10, 2026 | Joshua B CohenCo-Chief Executive Officer | 29.5K | $32.16 | $950.0K | Form 4 | |
| Sep 10, 2026 | Joshua B CohenCo-Chief Executive Officer | 919 | $33.15 | $30.5K | Form 4 | |
| Aug 31, 2026 | Karen FirestoneDirector | 25.0K | $1.76 | $44.0K | Form 4 | |
| Aug 31, 2026 | Karen FirestoneDirector | 25.0K | $5.05 | $126.3K | Form 4 | |
| Aug 18, 2026 | James M FratesChief Financial Officer | 22.8K | – | – | Form 4 | |
| Aug 18, 2026 | Justin B. KleeCo-Chief Executive Officer | 60.0K | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 26, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by AMLX's officers and directors from 2022 up to November 17, 2025, 4 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class15.0%
- Perceptive Advisors LLCwith 2 more personsShare of class7.50%
- BlackRock, Inc.Share of class7.10%
- TCG Crossover GP II, LLCwith 2 more personsShare of class5.70%
- Commodore Capital LPwith 3 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 15.0% | 16.47M | Feb 5, 20262 filings since Oct 7, 2025 | 13G/A | |
| Perceptive Advisors LLCwith 2 more persons | 7.50% | 8.28M | May 15, 20264 filings since Feb 14, 2025 | 13G/A | |
| BlackRock, Inc. | 7.10% | 7.78M | Jan 21, 20262 filings since Jul 17, 2025 | 13G/A | |
| TCG Crossover GP II, LLCwith 2 more persons | 5.70% | 6.24M | Feb 17, 2026 | 13G/A | |
| Commodore Capital LPwith 3 more persons | 5.10% | 5.65M | Nov 17, 2025 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+173%
- D.E. ShawIn the quarter+196%
- Millennium Mgmt (Englander)In the quarter
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter+69%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 388.7K | $11M | 0.02% | |
| Citadel Advisors (Griffin) | 488.6K | +173% | $14M | 0.01% |
| D.E. Shaw | 516.2K | +196% | $15M | 0.01% |
| Millennium Mgmt (Englander) | 191.7K | $5.6M | 0.00% | |
| Renaissance Technologies | 72.9K | $2.1M | 0.00% | |
| AQR Capital | 35.3K | +69% | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 10.3% of its shares outstanding were held short, +4.6% since the report before.
- Shares held short
- 13.25M
- 10.3%
- Since the report before12.67M on Sep 30, 2026
- +4.6%
- 9.9
- 1.33M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 91%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 7.93M
- Nov 15, 2023: Shares held short 7.07M
- Nov 30, 2023: Shares held short 6.94M
- Dec 15, 2023: Shares held short 6.66M
- Dec 29, 2023: Shares held short 5.44M
- Jan 12, 2024: Shares held short 5.73M
- Jan 31, 2024: Shares held short 5.44M
- Feb 15, 2024: Shares held short 4.98M
- Feb 29, 2024: Shares held short 4.37M
- Mar 15, 2024: Shares held short 5.09M
- Mar 28, 2024: Shares held short 6.01M
- Apr 15, 2024: Shares held short 6.51M
- Apr 30, 2024: Shares held short 8.51M
- May 15, 2024: Shares held short 7.99M
- May 31, 2024: Shares held short 7.57M
- Jun 14, 2024: Shares held short 7.21M
- Jun 28, 2024: Shares held short 4.57M
- Jul 15, 2024: Shares held short 3.78M
- Jul 31, 2024: Shares held short 1.86M
- Aug 15, 2024: Shares held short 1.97M
- Aug 30, 2024: Shares held short 1.49M
- Sep 13, 2024: Shares held short 1.26M
- Sep 30, 2024: Shares held short 1.28M
- Oct 15, 2024: Shares held short 1.01M
- Oct 31, 2024: Shares held short 1.29M
- Nov 15, 2024: Shares held short 1.53M
- Nov 29, 2024: Shares held short 1.45M
- Dec 13, 2024: Shares held short 1.57M
- Dec 31, 2024: Shares held short 1.94M
- Jan 15, 2025: Shares held short 2.48M
- Jan 31, 2025: Shares held short 2.59M
- Feb 14, 2025: Shares held short 3.38M
- Feb 28, 2025: Shares held short 3.65M
- Mar 14, 2025: Shares held short 3.75M
- Mar 31, 2025: Shares held short 3.78M
- Apr 15, 2025: Shares held short 4.31M
- Apr 30, 2025: Shares held short 4.20M
- May 15, 2025: Shares held short 4.97M
- May 30, 2025: Shares held short 4.13M
- Jun 13, 2025: Shares held short 4.04M
- Jun 30, 2025: Shares held short 6.62M
- Jul 15, 2025: Shares held short 7.47M
- Jul 31, 2025: Shares held short 7.19M
- Aug 15, 2025: Shares held short 7.43M
- Aug 29, 2025: Shares held short 8.41M
- Sep 15, 2025: Shares held short 8.77M
- Sep 30, 2025: Shares held short 10.07M
- Oct 15, 2025: Shares held short 9.62M
- Oct 31, 2025: Shares held short 10.45M
- Nov 14, 2025: Shares held short 11.91M
- Nov 28, 2025: Shares held short 11.62M
- Dec 15, 2025: Shares held short 12.07M
- Dec 31, 2025: Shares held short 13.64M
- Jan 15, 2026: Shares held short 13.44M
- Jan 30, 2026: Shares held short 13.75M
- Feb 13, 2026: Shares held short 14.31M
- Feb 27, 2026: Shares held short 14.50M
- Mar 13, 2026: Shares held short 13.86M
- Mar 31, 2026: Shares held short 14.23M
- Apr 15, 2026: Shares held short 14.83M
- Apr 30, 2026: Shares held short 14.80M
- May 15, 2026: Shares held short 14.51M
- May 29, 2026: Shares held short 14.96M
- Jun 15, 2026: Shares held short 13.12M
- Jun 30, 2026: Shares held short 14.39M
- Jul 15, 2026: Shares held short 12.27M
- Jul 31, 2026: Shares held short 13.40M
- Aug 14, 2026: Shares held short 13.43M
- Aug 31, 2026: Shares held short 12.74M
- Sep 15, 2026: Shares held short 13.51M
- Sep 30, 2026: Shares held short 12.67M
- Oct 15, 2026: Shares held short 13.25M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading54.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 54.5% of the shares in the reported trades were short sales, against 51.9% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 54.5%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 51.9%
- Change
- +2.6 pts
- Short sales a dayon average, of 634.6K shares
- 345.7K
- More than atof 3,666 US-listed companies, same days
- 65%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 57%
- Oct 12, 2026: Short sales 64.1%
- Oct 13, 2026: Short sales 72.9%
- Oct 14, 2026: Short sales 72.9%
- Oct 15, 2026: Short sales 63%
- Oct 16, 2026: Short sales 36.4%
- Oct 19, 2026: Short sales 34.9%
- Oct 20, 2026: Short sales 36.1%
- Oct 21, 2026: Short sales 73%
- Oct 22, 2026: Short sales 46.7%
- Oct 23, 2026: Short sales 26.9%
- Oct 26, 2026: Short sales 60.3%
- Oct 27, 2026: Short sales 63.9%
- Oct 28, 2026: Short sales 38.2%
- Oct 29, 2026: Short sales 57.7%
- Oct 30, 2026: Short sales 73.5%
- Nov 2, 2026: Short sales 60.6%
- Nov 3, 2026: Short sales 52.8%
- Nov 4, 2026: Short sales 36.2%
- Nov 5, 2026: Short sales 43.8%
- Nov 6, 2026: Short sales 40.8%
- Nov 9, 2026: Short sales 51%
- Nov 10, 2026: Short sales 55%
- Nov 11, 2026: Short sales 56%
- Nov 12, 2026: Short sales 73%
- Nov 13, 2026: Short sales 51.5%
- Nov 16, 2026: Short sales 78.2%
- Nov 17, 2026: Short sales 52.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Joshua B CohenCo-Chief Executive OfficerDirectly3.51M
- Justin B. KleeCo-Chief Executive OfficerDirectly3.51M
- George M Milne JrDirectorDirectly782.9K
- James M FratesChief Financial OfficerDirectly400.2K
- Camille L BedrosianChief Medical OfficerDirectly278.1K
- Patrick D YeramianChief Medical OfficerDirectly205.6K
- Gina MazzarielloChief Legal OfficerDirectly190.8K
- Karen FirestoneDirectorDirectly116.9K
- Bernhardt G ZeiherDirectorDirectly10.0K
- Daphne QuimiDirectorDirectly5,000
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Joshua B CohenCo-Chief Executive Officer | 3.51M | – | Nov 9, 2026 | Form 4 |
| Justin B. KleeCo-Chief Executive Officer | 3.51M | – | Nov 9, 2026 | Form 4 |
| George M Milne JrDirector | 782.9K | – | Oct 5, 2026 | Form 4 |
| James M FratesChief Financial Officer | 400.2K | – | Nov 10, 2026 | Form 4 |
| Camille L BedrosianChief Medical Officer | 278.1K | – | Sep 10, 2026 | Form 4 |
| Patrick D YeramianChief Medical Officer | 205.6K | – | Jan 9, 2024 | Form 4 |
| Gina MazzarielloChief Legal Officer | 190.8K | – | Sep 10, 2026 | Form 4 |
| Karen FirestoneDirector | 116.9K | – | Aug 31, 2026 | Form 4 |
| Bernhardt G ZeiherDirector | 10.0K | – | Mar 20, 2025 | Form 4 |
| Daphne QuimiDirector | 5,000 | – | May 15, 2024 | Form 4 |
A lower bound: it counts only the 10 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.35%
- IBBiShares Biotechnology ETFWeight in the fund0.13%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.11%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.10%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.07%
- IWMiShares Russell 2000 ETFWeight in the fund0.05%
- VHTVanguard Health Care Index FundWeight in the fund0.03%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.02%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.01%
16 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 170
- Q4 2025: Managers 180
- Q1 2026: Managers 173
- Q2 2026: Managers 207
Institutional investors by quarter
The fund managers holding AMLX, quarter by quarter, from Q2 2017 to Q2 2025, 18 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 207 managers held 115M shares, worth $2.1B. During the quarter 51 opened a position, 17 closed one, 68 added and 57 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+0.6%
- BlackRockIn the quarter
- Perceptive AdvisorsIn the quarter+0.6%
- TCG Crossover ManagementIn the quarter
- Commodore CapitalIn the quarter
- Jupiter TopcoIn the quarter
- Saturn V Capital ManagementIn the quarter+6.3%
- Vanguard Capital ManagementIn the quarter+2.0%
- Morgan StanleyIn the quarter+44%
- Driehaus Capital ManagementIn the quarter+1.7%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 16.73M | +0.6% | $300M |
| BlackRock | 8.83M | $159M | |
| Perceptive Advisors | 8.33M | +0.6% | $150M |
| TCG Crossover Management | 6.24M | $112M | |
| Commodore Capital | 5.65M | $101M | |
| Jupiter Topco | 5.24M | $94M | |
| Saturn V Capital Management | 4.62M | +6.3% | $83M |
| Vanguard Capital Management | 4.22M | +2.0% | $76M |
| Morgan Stanley | 3.13M | +44% | $56M |
| Driehaus Capital Management | 3.04M | +1.7% | $55M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Amylyx Pharmaceuticals's filings show?
Who buys and sells is one part of Amylyx Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have AMLX's insiders bought or sold?
From May 26, 2026 to Nov 12, 2026 Amylyx Pharmaceuticals's insiders bought $51.3K and sold $11M of shares on the market. 74% of the sales were under set 10b5-1 plans.
Which well-known managers hold AMLX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $15M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.